Scientists probe 'Durable Effect' of MS drugs on immune system
NCT ID NCT06586177
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 100 people with relapsing-remitting multiple sclerosis who are taking anti-CD20 drugs like ofatumumab or rituximab. Researchers will track changes in immune cells, proteins, and brain scans over time to understand how these therapies work long-term. The goal is to learn why some patients have better outcomes, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CD20 antibodies (ofatumumab, ocrelizumab, ublituximab, rituximab)
What this could lead to
If successful, this could help doctors understand why some patients respond better to B-cell therapies and how to personalize treatment for multiple sclerosis.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heinrich-Heine University, Duesseldorf
RECRUITINGDüsseldorf, 40225, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••